Shamburg News · 8-K filed Nov 12, 2026, 4:45 PM EST
InspireMD Reports Third Quarter 2026 Results and FDA Approval of CGuard Prime for TCAR
NSPR · InspireMD, Inc.
- Earnings
- Other event
- Materiality: high
InspireMD reported third quarter 2026 total revenue of $2,242,000, down from $2,523,000 a year earlier, and a net loss of $9,762,000, or $0.12 per basic and diluted share. The company reported cash and cash equivalents and marketable securities of $19,246,000 as of September 30, 2026. The release also announced FDA approval of CGuard Prime for TCAR procedures and attributed the U.S. revenue decline to a voluntary recall of the CGuard Prime for CAS delivery system.
Source: SEC EDGAR, Form 8-K, Items 2.02, 8.01, 9.01, accession 0001493152-26-051454.
Written from the filing by Shamburg Markets. Figures are as reported by the company.